Orakl Oncology

Orakl Oncology leverages tumor avatars, combining cutting-edge biology with large-scale, high-quality clinical and molecular data. Our biotechnology platform enables oncology stakeholders to identify relevant targets more quickly and deliver better drugs. Orakl Oncology is a spin-off from the world’s third-ranked cancer center, Gustave Roussy Institute, co-founded by a seasoned team of experts with decades of international experience in cancer cell biology and engineering.